二甲双胍缓释片不同联合用药方案治疗2型糖尿病成本-效果分析  

Cost-Effectiveness Analysis of Metformin Sustained Release Tablets in Combination with Different Drugs in the Treatment of Type 2 Diabetes

作　　者：沈勤炎[1] 

机构地区：[1]江苏省原子医学研究所附属江原医院药剂科,无锡市214063

出　　处：《中国医院用药评价与分析》2008年第7期522-523,共2页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:评价二甲双胍缓释片不同联合用药方案治疗2型糖尿病的成本-效果。方法:56例患者分成3组,分别给予二甲双胍+吡格列酮+门冬胰岛素30(A组)、二甲双胍+阿卡波糖+诺和灵30R(B组)、二甲双胍+罗格列酮+诺和灵30R(C组)治疗2周,进行成本-效果分析。结果:总有效率各组间无显著差异,A、B、C组成本-效果比分别为413.2、426.2、492.8,B、C组相对于A组的增量成本-效果比分别为1147.0、-8875。结论:A方案为较佳选择。OBJECTIVE： To evaluate the cost - effectiveness of metformin sustained release tablets in combination with different drugs in the treatment of type 2 diabetes. METHODS： A total of 56 patients were enrolled and randomized to Group A （metformin ＋ pioglitazone ＋ novomix 30）, Group B （metformin ＋ acarbose ＋ novolin 30）or Group C （metformin ＋ rosiglitazone ＋ novolin 30） . The cost- effectiveness of the 3 groups was evaluated after treatment for 2 weeks. RESULTS： There was no significant difference in the total effective rate among 3 schemes. The cost- effectiveness ratios in scheme A, B and C were 413.2,426.2 and 492.8, respectively. The cost - effectiveness ratio increments in scheme B and C were 1 147.0 and -8 875.0 as against scheme A. CONCLUSION： Scheme A is the preferable choice among the 3 schemes.

关 键 词：2型糖尿病 降糖药 成本-效果分析 

分 类 号：R977.15[医药卫生—药品]